Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone

Identification

Name
Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
Accession Number
DB02872  (EXPT01878)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 686.434
Monoisotopic: 684.09468089
Chemical Formula
C31H34Br2N4O4
InChI Key
PVRYEWOXWGDQHA-URLMMPGGSA-N
InChI
InChI=1S/C31H34Br2N4O4/c1-3-41-27-20-25(40-2)12-13-26(27)30-34-28(21-4-8-23(32)9-5-21)29(22-6-10-24(33)11-7-22)37(30)31(39)36-16-14-35(15-17-36)18-19-38/h4-13,20,28-29,38H,3,14-19H2,1-2H3/t28-,29+/m0/s1
IUPAC Name
2-{4-[(4S,5R)-4,5-bis(4-bromophenyl)-2-(2-ethoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl]piperazin-1-yl}ethan-1-ol
SMILES
[H][[email protected]]1(N=C(N(C(=O)N2CCN(CCO)CC2)[[email protected]]1([H])C1=CC=C(Br)C=C1)C1=C(OCC)C=C(OC)C=C1)C1=CC=C(Br)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UE3 ubiquitin-protein ligase Mdm2Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5288631
PubChem Substance
46507913
ChemSpider
4450754
BindingDB
50392531
ChEMBL
CHEMBL407632
HET
IMZ
PDB Entries
1rv1

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00547 mg/mLALOGPS
logP5.06ALOGPS
logP5.52ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)6.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area77.84 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity166.88 m3·mol-1ChemAxon
Polarizability65.61 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9915
Blood Brain Barrier+0.5935
Caco-2 permeable-0.5361
P-glycoprotein substrateSubstrate0.8255
P-glycoprotein inhibitor INon-inhibitor0.5093
P-glycoprotein inhibitor IIInhibitor0.6315
Renal organic cation transporterInhibitor0.5308
CYP450 2C9 substrateNon-substrate0.7307
CYP450 2D6 substrateNon-substrate0.8218
CYP450 3A4 substrateSubstrate0.5999
CYP450 1A2 substrateNon-inhibitor0.7705
CYP450 2C9 inhibitorNon-inhibitor0.659
CYP450 2D6 inhibitorNon-inhibitor0.8227
CYP450 2C19 inhibitorNon-inhibitor0.7251
CYP450 3A4 inhibitorNon-inhibitor0.7628
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5508
Ames testNon AMES toxic0.6789
CarcinogenicityNon-carcinogens0.7377
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6041 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6617
hERG inhibition (predictor II)Inhibitor0.662
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Stilbenes
Sub Class
Not Available
Direct Parent
Stilbenes
Alternative Parents
Piperazine carboxamides / Anisoles / Methoxybenzenes / Phenoxy compounds / Alkyl aryl ethers / Bromobenzenes / N-alkylpiperazines / Aryl bromides / Imidazolines / Ureas
show 11 more
Substituents
Stilbene / Piperazine-1-carboxamide / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Bromobenzene / Halobenzene / N-alkylpiperazine
show 33 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by bindi...
Gene Name
MDM2
Uniprot ID
Q00987
Uniprot Name
E3 ubiquitin-protein ligase Mdm2
Molecular Weight
55232.39 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 15:04